The day at a glance · 3 min read
Mood · Mixed
-15
Sentiment, −100 to +100
Lilly PA Facility Investment
$3.5B
Lilly U.S. Manufacturing Push
$50B
Jefferies LLY Price Target
$1,700
Key driverMajor manufacturing investments by Eli Lilly offset by Moderna's elevated cash burn guidance for oncology expansion
Daily briefHealthcare· Money365.Market AI ·

Lilly Expands Manufacturing, Moderna Falls on Cancer Costs

Eli Lilly breaks ground on $3.5 billion obesity medicine facility while Moderna shares fall 7% on oncology spending guidance.

Big Pharma Manufacturing & Pipeline

Bullish

BMY 3-Year Return

40.5%
01LLY
Eli Lilly (LLY) broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley, one of ten new U.S. manufacturing sites announced since 2020. The site is part of the company's $50 billion push to expand medicine production in the U.S. and will add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GLP-1 therapy.
02LLY
Jefferies raised its price target on Eli Lilly (LLY) to $1,700, positioning the stock among unrivaled stocks for the next decade.
03BMY
Bristol Myers Squibb (BMY) traded at $62.91, with the stock returning approximately 40.5% over the past three years, supported by fresh data for key therapies and a solid pipeline story. Recent trial results for therapies have helped justify the step up in market value, though investors continue to assess whether current pricing is backed by cash flow generation over time.

Biotech Funding & Clinical Development

Neutral

Moderna 2027 Cash Costs

$4B

Windward IPO Proceeds

$175M

Compugen Q3 Revenue

$3.8M

Compugen Cash Position

$117.5M

Assembly Gilead Extension Fee

$75M
01MRNA▼ -6.97%
Moderna (MRNA) shares fell 7% after the company guided to cash costs of approximately $4 billion in 2027 and $4 billion to $4.5 billion annually through 2030, mostly for oncology. The company is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck (MRK) if regulators approve the therapy.
02MRNA▼ -6.97%
Moderna (MRNA) raised its 2026 revenue growth outlook and is scheduled to join the MSCI World Index in November 2026, adding the stock to a major global benchmark.
03AMGN
Windward, a Swiss biotech, priced a $175 million IPO to advance China-licensed lung drugs, with two prospects the company sees as having the potential to outcompete AstraZeneca and Amgen's (AMGN) blockbuster asthma treatment Tezspire.
04CGEN
Compugen (CGEN) posted $3.8 million in Q3 2026 revenue as partnerships with Gilead (GILD) and AstraZeneca advanced. The company completed MAIA-ovarian enrollment with data expected by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.
05GILD
Assembly Biosciences (ASMB) initiated a Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection and exercised a 40% U.S. profit-share option for the HSV helicase primase inhibitor program. The company received a first $75 million collaboration extension fee from Gilead (GILD), with cash runway projected into 2029.

Patent Litigation & IP

Neutral
01PFE▼ -2.11%
GSK reached a cross-licensing agreement with Moderna (MRNA) resolving their COVID-19 vaccine patent dispute in Europe. The pharma group secured a significant injunction against Pfizer (PFE)-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets. Ongoing legal actions and expected appeals around this RNA and liposome IP framework now shape how the largest vaccine makers operate in Europe.

Clinical Trial Readouts

Bullish
01REGN
Regeneron (REGN) presented Phase 2 trial data at the American Autonomic Society annual meeting showing baloncibart, a first-in-class NPR1 blocking antibody, reduced orthostatic heart rate and improved orthostatic symptoms in POTS (postural orthostatic tachycardia syndrome). A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks, with biomarker changes consistent with plasma volume expansion. POTS is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments currently available.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy